Latest News Archive

Please select Category, Year, and then Month to display items

The first clinical PhD in nuclear medicine completed at the UFS

18 April 2024 | Story Andre Damons | Photo Charl Devenish

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans.

News Archive

Carbon dioxide makes for more aromatic decaffeinated coffee

2017-10-27

The Inorganic Group in the Department of Chemistry
at the UFS is systematically researching the utilisation
of carbon dioxide. From the left, are, Dr Ebrahiem Botha,
Postdoctoral Fellow; Mahlomolo Khasemene, MSc student;
Prof André Roodt; Dr Marietjie Schutte-Smith, Senior Lecturer;
and Mokete Motente, MSc student.
Photo: Charl Devenish

Several industries in South Africa are currently producing hundreds of thousands of tons of carbon dioxide a year, which are released directly into the air. A typical family sedan doing around 10 000 km per year, is annually releasing more than one ton of carbon dioxide into the atmosphere.

The Inorganic Chemistry Research Group in the Department of Chemistry at the University of the Free State (UFS), in collaboration with the University of Zurich in Switzerland, has focused in recent years on using carbon dioxide – which is regarded as a harmful and global warming gas – in a meaningful way.

According to Prof André Roodt, Head of Inorganic Chemistry at the UFS, the Department of Chemistry has for the past five decades been researching natural products that could be extracted from plants. These products are manufactured by plants through photosynthesis, in other words the utilisation of sunlight and carbon dioxide, nitrogen, and other nutrients from the soil.

Caffeine and chlorophyll
“The Inorganic group is systematically researching the utilisation of carbon dioxide. Carbon dioxide is absorbed by plants through chlorophyll and used to make interesting and valuable compounds and sugars, which in turn could be used for the production of important new medicines,” says Prof Roodt.

Caffeine, a major energy enhancer, is also manufactured through photosynthesis in plants. It is commonly found in tea and coffee, but also (artificially added) in energy drinks. Because caffeine is a stimulant of the central nervous system and reduces fatigue and drowsiness, some people prefer decaffeinated coffee when enjoying this hot drink late at night.

Removing caffeine from coffee could be expensive and time-consuming, but also environmentally unfriendly, because it involves the use of harmful and flammable liquids. Some of the Inorganic Group’s research focus areas include the use of carbon dioxide for the extraction of compounds, such as caffeine from plants.

“Therefore, the research could lead to the availability of more decaffeinated coffee products. Although decaffeinated coffee is currently aromatic, we want to investigate further to ensure better quality flavours,” says Prof Roodt.

Another research aspect the team is focusing on is the use of carbon dioxide to extract chlorophyll from plants which have medicinal properties themselves. Chemical suppliers sell chlorophyll at R3 000 a gram. “In the process of investigating chlorophyll, our group discovered simpler techniques to comfortably extract larger quantities from green vegetables and other plants,” says Prof Roodt.

Medicines
In addition, the Inorganic Research Group is also looking to use carbon dioxide as a building block for more valuable compounds. Some of these compounds will be used in the Inorganic Group’s research focus on radiopharmaceutical products for the identification and possibly even the treatment of diseases such as certain cancers, tuberculosis, and malaria.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept